David R Spigel, MD
Hanna N et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24(13):2038-43. Abstract
Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379(23):2220-9. Abstract
Liu SV et al. IMpower 133: Primary PFS, OS and safety in a PH1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC. WCLC 2018;Abstract PL02.07.
Mok TSK et al. IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Proc ESMO Asia 2018;Abstract LBA1.
Noda K et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346(2):85-91. Abstract
Paz-Ares L et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomized, controlled, open-label, phase 3 trial. Lancet 2019;[Epub ahead of print]. Abstract
Schwartz LH et al. RECIST 1.1 — Update and clarification: From the RECIST committee. Eur J Cancer 2016;62:132-7. Abstract
Slotman B et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: A phase 3 randomized controlled trial. Lancet 2015;385(9962);36-42. Abstract
Slotman B et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357(7):664-72. Abstract
Ramaswamy Govindan, MD
Antonio SJ. Immune checkpoint blockade for SCLC: State of the art. WCLC 2019;Abstract MS09.01.
Antonia SJ et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicenter, open-label, phase 1/2 trial. Lancet Oncol 2016;17(7):883-95. Abstract
Byers L et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012;2(9):798-811. Abstract
Cardnell RJ et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 2013;19(22):6322-8. Abstract
George J et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524(7563):47-53. Abstract
Linnoila RI. Functional facets of the pulmonary neuroendocrine system. Lab Invest 2006;86(5):425-44. Abstract
Lok BH et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res 2017;23(2):523-35. Abstract
Meder L et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer 2016;138(4):927-38. Abstract
Melichar B et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-esophageal adenocarcinoma: A five-arm phase 2 study. Lancet Oncol 2015;16(4):395-405. Abstract
Ott PA et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study. J Clin Oncol 2017;35(34):3823-9. Abstract
Owonikoko T et al. SLFN11 expression and efficacy of PARP inhibitor therapy in extensive stage small-cell lung cancer: ECOG-ACRIN 2511 study. WCLC 2018;Abstract P3.12-06.
Pietanza MC et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 2018;36(23):2386-94. Abstract
Pietanza MC et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012;18(4):1138-45. Abstract
Reck M et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331. Proc ESMO Immuno-Oncology 2018;Abstract LBA5.
Saunders LR et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 2015;7(302):302ra136. Abstract
Wagner AH et al. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Commun 2018;9(1):3787. Abstract
Anna Farago, MD, PhD
Boutros C et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016;13(8):473-86. Abstract
Hellmann MD et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 2018. Abstract
Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379(23):2220-9. Abstract
Martins F et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16(9):563-80. Abstract
Owonikoko TK et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase 3 CheckMate 451 study. IASLC 2019;Abstract LBA1_PR.
Paz-Ares L et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomized, controlled, open-label, phase 3 trial. Lancet 2019;[Epub ahead of print]. Abstract
Postow MA et al. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378(2):158-68. Abstract
Reck M et al. IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). ESMO 2019;Abstract 1736O.
Reck M et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small-cell lung cancer (SCLC): Results from CheckMate 331. Proc ESMO Immuno-Oncology 2018;Abstract LBA5.